Agios Pharmaceuticals (NASDAQ:AGIO) Raised to "Hold" at StockNews.com

StockNews.com upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO - Free Report) from a sell rating to a hold rating in a research note released on Saturday.

Several other equities research analysts have also recently weighed in on the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $55.00 target price on shares of Agios Pharmaceuticals in a report on Friday, November 1st. Cantor Fitzgerald reiterated an "overweight" rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Raymond James reiterated an "outperform" rating and issued a $51.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Scotiabank upped their target price on Agios Pharmaceuticals from $51.00 to $53.00 and gave the stock a "sector outperform" rating in a report on Friday, November 1st. Finally, Leerink Partnrs lowered Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 27th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $52.33.

Agios Pharmaceuticals Trading Up 7.2 %

Shares of AGIO stock traded up $3.98 on Friday, reaching $59.06. 1,692,323 shares of the company's stock were exchanged, compared to its average volume of 519,589. Agios Pharmaceuticals has a 52 week low of $20.40 and a 52 week high of $60.21. The stock has a market capitalization of $3.37 billion, a PE ratio of 5.20 and a beta of 0.75. The company's fifty day simple moving average is $45.15 and its 200 day simple moving average is $42.98.

Insider Transactions at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 2,542 shares of the company's stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares of the company's stock, valued at $988,346.74. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 4.93% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Caxton Associates LP increased its holdings in shares of Agios Pharmaceuticals by 0.7% in the second quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company's stock valued at $1,615,000 after purchasing an additional 264 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Agios Pharmaceuticals by 0.8% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 39,248 shares of the biopharmaceutical company's stock valued at $1,148,000 after purchasing an additional 314 shares during the period. CANADA LIFE ASSURANCE Co increased its holdings in shares of Agios Pharmaceuticals by 1.8% in the first quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company's stock valued at $911,000 after purchasing an additional 540 shares during the period. Acadian Asset Management LLC acquired a new position in shares of Agios Pharmaceuticals in the second quarter valued at about $37,000. Finally, Quest Partners LLC acquired a new position in shares of Agios Pharmaceuticals in the second quarter valued at about $40,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.